GHTC delivers statement on NTDs road map at HHS WHA listening session

GHTC delivered the following statement, on the 75th World Health Assembly (WHA) agenda item 14.5 Immunization Agenda 2030, on May 13, 2022 at the US Department of Health and Human Services (HHS) WHA stakeholder listening session:Thank you once again for the opportunity to provide feedback on this important agenda item. Many recent scientific and multilateral agency reports and publications suggest that overall, immunization took a step backward in the past two years. Despite the tireless efforts of countless immunization program staff and health workers to ensure the availability of vaccination services, vaccination coverage globally fell for the first time in a decade. The COVID-19 pandemic has overwhelmed immunization infrastructure and workforce, impacted the global supply chain, increased the incidence of antimicrobial resistance, and derailed gains made in immunization campaigns around the world. Therefore, GHTC calls on the United States to:    Focus on the full spectrum of innovations that support immunization programs. The near term will inevitably be dominated by a continuing focus on COVID-19 vaccine rollouts. Nevertheless, it is vital that these activities are also leveraged to strengthen vaccine manufacturing capacities to address a broader range of health areas. This also includes storage, administration, and coadministration with other health interventions as well as novel service delivery, including focused “test & vaccinate” strategies as recently recommended by the Gavi board.  Support the development of formal feedback loops to monitor follow up and implementation of recommendations made by the WHO Strategic Advisory Group of Experts on Immunization and other regional immunization technical advisory groups.  Accelerate and expand the COVAX facility research and development agenda to advance next-generation COVID-19 vaccines, including “variant-proof” COVID-19 vaccines and shots that could provide wide protection against coronaviruses, vaccines with optimized dosing, and vaccines more suitable for delivery in low-resource settings. World leaders must also do everything in their power to correct the shameful lack of equitable access to these lifesaving tools.  

GHTC submitted the following statement online as part of the US Department of Health and Human Services (HHS) 75th World Health Assembly (WHA) stakeholder listening session in response to a draft WHA resolution proposed by the United Kingdom:While the pandemic has disrupted and delayed many research activities, it has also highlighted the importance of quality clinical trials in responding to public health threats nationally, regionally, and globally. Leaders recognize the need for additional investment, new capacities, and reform of existing systems to create a stronger enabling environment for research and development (R&D) in low- and middle-income countries. As countries seek to develop a more responsive and resilient global health architecture, it is vital to bolster regionally distributed clinical trial capacity. This resolution on strengthening clinical trials to improve public health is a strong first step, taking concrete action to facilitate investment in high-quality clinical trials, adopt robust clinical trial standards in routine practice to expedite the development of effective health care interventions, and develop the governance infrastructure to support enhanced collaboration and coordination between nations.  We urge the United States to support the resolution and to: Endorse the provision in the resolution calling for grant funding for clinical trials to be linked to required use of standard data protocols where available. Work with the World Health Organization and other member states to support the provision highlighting the need for data sharing between regulatory authorities to speed up and harmonize clinical trial approvals in other countries. Support greater clinical trial capacity globally through investment and technical support, enabling a greater number of clinical trial sites in lower- and middle-income countries and more readily coordinating activity between existing and new clinical trial networks. Elevate the Global Health Security Agenda as a platform where lower- and middle-income countries can articulate investment opportunities, highlight bottlenecks, share best practices, and align around R&D capacity assessment needs.